Philogen S.P.A.

Philogen S.P.A. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients. At present, Philogen has four promising anti-cancer antibody derivatives and an antibody derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies are in planning. Our Zurich-based daughter company Philochem serving as the R&D unit isolates the most promising candidate products, while in Siena (Italy) the pharmaceuticals are produced according to GMP standards and advanced to clinical trials. Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents.

Company Details

Employees
163
Founded
-
Address
Loc. Bellaria, 35, Sovicille,siena 53018,italy
Phone
(+39) 0577.1781.6
Email
in****@****ogen.it
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
GSK.
HQ
Sovicille, SIENA
Looking for a particular Philogen S.P.A. employee's phone or email?

Philogen S.p.a. Questions

News

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus r - GlobeNewswire

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus r GlobeNewswire

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells - Wiley

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells Wiley

Sun Pharma, Philogen complete patient enrollment for Cancer Drug Phase-3 Trials, results expected by Q1 FY26 - ET Pharma

Sun Pharma, Philogen complete patient enrollment for Cancer Drug Phase-3 Trials, results expected by Q1 FY26 ET Pharma

Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy - Pharmaceutical Executive

Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy Pharmaceutical Executive

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer - Newswire.com

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer Newswire.com

Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation - PR Newswire

Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation PR Newswire

Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy | Bioconjugate Chemistry - ACS Publications

Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy | Bioconjugate Chemistry ACS Publications

Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen - Taylor & Francis Online

Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen Taylor & Francis Online

White & Case Advises Philogen on First Italian Main Market IPO of 2021 - White & Case LLP

White & Case Advises Philogen on First Italian Main Market IPO of 2021 White & Case LLP

Neoadjuvant Daromun Elicits RFS Benefit in Locally Advanced, Fully Resectable Melanoma - OncLive

Neoadjuvant Daromun Elicits RFS Benefit in Locally Advanced, Fully Resectable Melanoma OncLive

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich - Yahoo Finance

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich Yahoo Finance

Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors - Journal of Nuclear Medicine

Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors Journal of Nuclear Medicine

Philogen S.p.A. announces receipt of the Good Manufacturing - GlobeNewswire

Philogen S.p.A. announces receipt of the Good Manufacturing GlobeNewswire

Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation - Newswire.com

Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation Newswire.com

Permutational Encoding Strategy Accelerates HIT Validation from Single-Stranded DNA-Encoded Libraries - ACS Publications

Permutational Encoding Strategy Accelerates HIT Validation from Single-Stranded DNA-Encoded Libraries ACS Publications

Philogen to Present at UBS Global Healthcare Conference - GlobeNewswire

Philogen to Present at UBS Global Healthcare Conference GlobeNewswire

Philogen and The Scripps Research Institute Announce Research Collaboration in the Field of DNA-Encoded Chemistry - Newswire.com

Philogen and The Scripps Research Institute Announce Research Collaboration in the Field of DNA-Encoded Chemistry Newswire.com

Philogen Announces R&D Program Update - GlobeNewswire

Philogen Announces R&D Program Update GlobeNewswire

Philochem and Blue Earth Diagnostics Announce First Three - GlobeNewswire

Philochem and Blue Earth Diagnostics Announce First Three GlobeNewswire

Philogen Provides Corporate Update - GlobeNewswire

Philogen Provides Corporate Update GlobeNewswire

Earnings call transcript: Philogen SpA’s Q2 2025 showcases strong cash position - Investing.com

Earnings call transcript: Philogen SpA’s Q2 2025 showcases strong cash position Investing.com

Philogen S.p.A. Updates Share Buyback Program - TipRanks

Philogen S.p.A. Updates Share Buyback Program TipRanks

Risk Hedge: Is Philogen S.p.A. (78Q) stock undervalued after correction - Treasury Yields & Comprehensive Market Scan Reports - Trung tâm Dự báo KTTV quốc gia

Risk Hedge: Is Philogen S.p.A. (78Q) stock undervalued after correction - Treasury Yields & Comprehensive Market Scan Reports Trung tâm Dự báo KTTV quốc gia

Philogen - The Pharma Letter

Philogen The Pharma Letter

What RSI levels show for Philogen S.p.A. (78Q) stock - 2025 Buyback Activity & Consistent Income Trade Ideas - Trung tâm Dự báo KTTV quốc gia

What RSI levels show for Philogen S.p.A. (78Q) stock - 2025 Buyback Activity & Consistent Income Trade Ideas Trung tâm Dự báo KTTV quốc gia

Is Philogen S.p.A. (78Q) stock undervalued after correction - 2025 Trade Ideas & Free Community Consensus Stock Picks - Trung tâm Dự báo KTTV quốc gia

Is Philogen S.p.A. (78Q) stock undervalued after correction - 2025 Trade Ideas & Free Community Consensus Stock Picks Trung tâm Dự báo KTTV quốc gia

Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma - Science | AAAS

Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma Science | AAAS

Philogen (BIT:PHIL) Faces Projected 47.9% Annual Revenue Decline Heading Into Earnings Season - simplywall.st

Philogen (BIT:PHIL) Faces Projected 47.9% Annual Revenue Decline Heading Into Earnings Season simplywall.st

Italian cancer startup Philogen gets off an impressive $70M funding round - Fierce Biotech

Italian cancer startup Philogen gets off an impressive $70M funding round Fierce Biotech

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy - ScienceDirect.com

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy ScienceDirect.com

Sun Pharma, Philogen complete patient enrollment in Phase III trial for Soft Tissue Sarcoma - Medical Dialogues

Sun Pharma, Philogen complete patient enrollment in Phase III trial for Soft Tissue Sarcoma Medical Dialogues

Sun Pharma partner Philogen withdraws EU application for skin cancer drug - Business Standard

Sun Pharma partner Philogen withdraws EU application for skin cancer drug Business Standard

Sun Pharma partners with Philogen to commercialise anti-cancer immunotherapy Fibromun - BioSpectrum India

Sun Pharma partners with Philogen to commercialise anti-cancer immunotherapy Fibromun BioSpectrum India

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand - The Economic Times

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand The Economic Times

Sun Pharma and Philogen complete patient enrollment for Phase III soft tissue sarcoma trial - Express Pharma

Sun Pharma and Philogen complete patient enrollment for Phase III soft tissue sarcoma trial Express Pharma

SUNPHARMA AND PHILOGEN ENTERED INTO A LICENSING AGREEMENT TO COMMERCIALIZE FIBROMUN - ICICI Direct

SUNPHARMA AND PHILOGEN ENTERED INTO A LICENSING AGREEMENT TO COMMERCIALIZE FIBROMUN ICICI Direct

Sun Pharma and Philogen sign global licensing agreement for Fibromun - Express Pharma

Sun Pharma and Philogen sign global licensing agreement for Fibromun Express Pharma

Sun Pharma and Philogen enter into exclusive agreement for commercialising anti-cancer immunotherapy - financialexpress.com

Sun Pharma and Philogen enter into exclusive agreement for commercialising anti-cancer immunotherapy financialexpress.com

Sun Pharma signs licensing pact with Philogen for cancer medication - Business Standard

Sun Pharma signs licensing pact with Philogen for cancer medication Business Standard

Sun Pharma inks global licensing agreement to commercialise Philogen's anti-cancer immunotherapy - CNBC TV18

Sun Pharma inks global licensing agreement to commercialise Philogen's anti-cancer immunotherapy CNBC TV18

Sun Pharma to commercialise Philogen’s anti-cancer drug in Europe, Australia and New Zealand - CNBC TV18

Sun Pharma to commercialise Philogen’s anti-cancer drug in Europe, Australia and New Zealand CNBC TV18

Sun Pharma: Strikes a global deal with Philogen for cancer immunotherapy, Fibromun - BusinessLine

Sun Pharma: Strikes a global deal with Philogen for cancer immunotherapy, Fibromun BusinessLine

Sun Pharma Signs Global Licensing Deal for Philogen's Anti-Cancer Immunotherapy, Shares Down 1% - Equitypandit

Sun Pharma Signs Global Licensing Deal for Philogen's Anti-Cancer Immunotherapy, Shares Down 1% Equitypandit

Sun Pharma, Philogen sign agreement for commercialising Nidlegy in Europe, Australia and New Zealand - Free Press Journal

Sun Pharma, Philogen sign agreement for commercialising Nidlegy in Europe, Australia and New Zealand Free Press Journal

Milan: downbeat day for Philogen - Borsa Italiana

Milan: downbeat day for Philogen Borsa Italiana

Milan: major selling for Philogen - Borsa Italiana

Milan: major selling for Philogen Borsa Italiana

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant